REGULAR STRENGTH ANALGESIC & MUSCLE RELAXANT CAPLETS TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

IBUPROFEN; METHOCARBAMOL

제공처:

TEVA CANADA LIMITED

ATC 코드:

M03BA53

INN (International Name):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

복용량:

200MG; 500MG

약제 형태:

TABLET

구성:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

관리 경로:

ORAL

패키지 단위:

18/40

처방전 유형:

OTC

치료 영역:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

제품 요약:

Active ingredient group (AIG) number: 0248961001; AHFS:

승인 상태:

CANCELLED PRE MARKET

승인 날짜:

2015-11-25

제품 특성 요약

IMPORTANT: PLEASE READ
1 | P a g e
PRODUCT MONOGRAPH
REGULAR STRENGTH ANALGESIC & MUSCLE
RELAXANT CAPLETS
METHOCARBAMOL AND IBUPROFEN TABLETS
500 MG/200 MG
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED,
Date of Preparation:
30 Novopharm Court
March 5, 2013
Toronto, Canada
M1B 2K9
Control# 161027
IMPORTANT: PLEASE READ
2 | P a g e
TABLE
OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
..................................................................................................3
ADVERSE
REACTIONS..................................................................................................10
DRUG
INTERACTIONS..................................................................................................12
DOSAGE AND
ADMINISTRATION..............................................................................15
OVERDOSAGE
...............................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
...........................................................18
STORAGE AND
STABILITY.........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................22
PART II: SCIENTIFIC
INFORMATION....................................................................21
PHARMACEUTICAL
INFORMATION..........................................................................21
CLINICAL
TRIALS..........................................................................................................23
DETAILED
PHARMACOLOGY........................................